Zetta Genomics Seed

Select partners: Sano, University of Cambridge, Microsoft, Genomics England, mongoDB.
Primary contact
50/60 Station Road
C/O HCR Hewitsons
CB1 2JH Cambridge
United Kingdom
+44 7779 663045
50/60 Station Road
C/O HCR Hewitsons
CB1 2JH Cambridge
United Kingdom
+44 7779 663045
Funding π°
Total Β£5.65M
Select investors Nina Capital, APEX Ventures, University of Cambridge Enterprise, Parkwalk Advisors, Innovate UK
Key people π§βπ€βπ§
- Will Spooner - CEO
- Ludo Chapman - Chair
- Ignacio Medina - Founder & CTO
- Bryony Burrows - CFO
- Leanne Elske - Head of Talent
Highlights β
- Solving the real problem: Legacy IT cannot scale to meet the exacting demands of genomic data at scale. Zetta's technology saves the valuable time of bioinformaticians and enables safe and convenient access to the large amounts of complex data they need to conduct the lab's life-changing research.
- Riding the rising wave: Genomic medicine has been on the roll in recent years, and Zetta Genomics has "what it takes" to benefit from the growth of this market, with its offering targeting multiple sectors - including genomic healthcare, biomedical research and pharmaceutical R&D.
- Leadership team with a solid track-record: CEO Will Spooner previously co-founded Eagle Genomics, has been a board member for ten years, and was head of innovation at Genomics England. Chair, Ludo Chapman, has led businesses through virtually every stage of growth, from driving successful start-ups to revitalising established companies.
In the news π°
Quotes π¬
“
Genomic medicine has enjoyed explosive growth in the past five years, but this is set to be eclipsed in the next decade. XetaBase is an enabling technology - empowering virtually every research field and clinical application. As genomic sequencing moves from the hundreds of thousands to the hundreds of millions, Nina Capital is confident that Zetta Genomics' growth will both drive and be driven by rapid advances in precision medicine.
— Marc Subirats, Partner at Nina Capital π
“
From our first meeting it was clear that Ignacio [Founder & CTO] had developed something incredibly special. Zetta's technology helps researchers and clinicians fully exploit genomic data, speeding the delivery of precision medicine across the world.
— Dr Elaine Loukes, Investment Director at University of Cambridge Enterprise π
Last update: April 21, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more